No Data
No Data
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $5
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $5 to $20
Cautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab's Efficacy and Dosing
ACELYRIN Is Maintained at Neutral by Citigroup
Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3
Nasdaq Down 1.5%; RPM Posts Upbeat Results